

EMA/132877/2020

European Medicines Agency decision

P/0126/2020

of 3 April 2020

on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for pracinostat (EMEA-002567-PIP01-19) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

Disclaimer

This decision does not constitute entitlement to the rewards and incentives referred to in Title V of Regulation (EC) No 1901/2006.

Only the English text is authentic.

European Medicines Agency decision

P/0126/2020

of 3 April 2020

on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for pracinostat (EMA-002567-PIP01-19) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

The European Medicines Agency,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No. 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004¹,

Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency²,

Having regard to the application submitted by Helsinn Birex Pharmaceuticals limited on 25 March 2019 under Article 16(1) of Regulation (EC) No 1901/2006 also requesting a deferral under Article 20 of said regulation and a waiver under Article 13 of said Regulation,

Having regard to the opinion of the Paediatric Committee of the European Medicines Agency, issued on 28 February 2020, in accordance with Article 17 of Regulation (EC) No 1901/2006 and Article 21 of said Regulation and Article 13 of said Regulation,

Having regard to Article 25 of Regulation (EC) No 1901/2006,

Whereas:

- (1) The Paediatric Committee of the European Medicines Agency has given an opinion on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver.
- (2) It is therefore appropriate to adopt a decision agreeing a paediatric investigation plan.
- (3) It is therefore appropriate to adopt a decision granting a deferral.
- (4) It is therefore appropriate to adopt a decision granting a waiver.

¹ OJ L 378, 27.12.2006, p.1.

² OJ L 136, 30.4.2004, p. 1.

Has adopted this decision:

Article 1

A paediatric investigation plan for pracinostat, capsule, hard, granules for oral suspension, oral use, gastric use, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby agreed.

Article 2

A deferral for pracinostat, capsule, hard, granules for oral suspension, oral use, gastric use, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby granted.

Article 3

A waiver for pracinostat, capsule, hard, granules for oral suspension, oral use, gastric use, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby granted.

Article 4

This decision is addressed to Helsinn Birex Pharmaceuticals limited, Damastown, Mulhuddart, 15 – Dublin, Ireland.



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

EMA/PDCO/688576/2019

Amsterdam, 28 February 2020

Opinion of the Paediatric Committee on the agreement of a Paediatric Investigation Plan and a deferral and a waiver

EMA-002567-PIP01-19

Scope of the application

Active substance(s):

Pracinostat

Condition(s):

Treatment of acute myeloid leukaemia

Pharmaceutical form(s):

Capsule, hard

Granules for oral suspension

Route(s) of administration:

Oral use

Gastric use

Name/corporate name of the PIP applicant:

Helsinn Birex Pharmaceuticals limited

Basis for opinion

Pursuant to Article 16(1) of Regulation (EC) No 1901/2006 as amended, Helsinn Birex Pharmaceuticals limited submitted for agreement to the European Medicines Agency on 25 March 2019 an application for a paediatric investigation plan for the above mentioned medicinal product and a deferral under Article 20 of said Regulation and a waiver under Article 13 of said Regulation.

The procedure started on 30 April 2019.

Supplementary information was provided by the applicant on 29 November 2019. The applicant proposed modifications to the paediatric investigation plan.



Opinion

1. The Paediatric Committee, having assessed the proposed paediatric investigation plan in accordance with Article 17 of Regulation (EC) No 1901/2006 as amended, recommends as set out in the appended summary report:

- to agree the paediatric investigation plan in accordance with Article 17(1) of said Regulation;
- to grant a deferral in accordance with Article 21 of said Regulation;
- to grant a waiver for one or more subsets of the paediatric population in accordance with Article 13 of said Regulation and concluded in accordance with Article 11(1)(b) of said Regulation, on the grounds that the disease or condition for which the specific medicinal product is intended does not occur in the specified subset(s) of the paediatric population.

The Norwegian Paediatric Committee member agrees with the above-mentioned recommendation of the Paediatric Committee.

2. The measures and timelines of the agreed paediatric investigation plan and the subset(s) of the paediatric population and condition(s) covered by the waiver are set out in the Annex I.

This opinion is forwarded to the applicant and the Executive Director of the European Medicines Agency, together with its annex and appendix.

Annex I

The subset(s) of the paediatric population and condition(s) covered by the waiver and the measures and timelines of the agreed paediatric investigation plan (PIP)

1. Waiver

1.1. Condition:

Treatment of acute myeloid leukaemia (AML)

The waiver applies to:

- the paediatric population from birth to less than 6 months of age;
- capsule, hard, granules for oral suspension, oral use, gastric use;
- on the grounds that the disease or condition for which the specific medicinal product is intended does not occur in the specified paediatric subset(s).

2. Paediatric investigation plan

2.1. Condition:

Treatment of acute myeloid leukaemia

2.1.1. Indication(s) targeted by the PIP

Treatment, in combination with azacitidine, of children with relapsed acute myeloid leukaemia who are refractory to re-induction chemotherapy or who relapse for a second time

2.1.2. Subset(s) of the paediatric population concerned by the paediatric development

From 6 months to less than 18 years of age.

2.1.3. Pharmaceutical form(s)

Capsule, hard

Granules for oral suspension

2.1.4. Measures

Area	Number of measures	Description
Quality-related studies	1	Study 1 Development of granules for oral suspension.
Non-clinical studies	0	Not applicable.

Area	Number of measures	Description
Clinical studies	2	Study 2 Open-label, single arm, multiple dose, two part trial to evaluate a recommended phase 2 dose (RP2D), pharmacokinetics, safety, acceptability/palatability of pracinostat in combination with azacitidine (part 1) and activity (part 2) in paediatric patients from 6 months to less than 18 years of age with relapsed acute myeloid leukaemia who are refractory to re-induction chemotherapy or after second relapse. Study 3 Open-label, single arm, external controlled trial to evaluate safety, and efficacy of pracinostat in combination with azacitidine in paediatric patients from 6 months to less than 18 years of age with relapsed acute myeloid leukaemia who are refractory to re-induction chemotherapy or after second relapse.
Extrapolation, modelling and simulation studies	1	Study 4 Modelling and simulation (Population PK) study to confirm or modify the paediatric posology for pracinostat in combination with azacitidine in children from 6 months to less than 18 years of age with relapsed AML who are refractory to re-induction chemotherapy or after second relapse.
Other studies	0	Not applicable.
Other measures	0	Not applicable.

3. Follow-up, completion and deferral of PIP

Concerns on potential long term safety/efficacy issues in relation to paediatric use:	Yes
Date of completion of the paediatric investigation plan:	By December 2035
Deferral for one or more measures contained in the paediatric investigation plan:	Yes